Determining common variants in patients with haemophilia A in South Vietnam and screening female carriers in their family members

Bang Suong Thi Nguyen,1,2 Xuan Thao Thi Le,1,2 Nghia Huynh,1 Huy Huu Nguyen,2 Cong-Minh Truong Nguyen,1,2 Bac Hoang Nguyen1,2

ABSTRACT

Aims The aim of this study was to determine common variants in F8, including intron 22 inversion (Inv22), intron 1 inversion (Inv1) and point mutations, the transmission of these variants between patients with haemophilia A (HA) and their family members.

Methods Genetic analysis was conducted in 71 patients who were clinically diagnosed with HA and 152 related female members in South Vietnam by a combination of inversion PCR (I-PCR), multiplex PCR and direct sequencing.

Results Variants in F8, including Inv22, point mutations (with 37 genotypes) and two novel variants, occupied 60 patients with HA. Among severe patients, the rate of Inv22 was 44%. Missense was the common point mutation of over 50% in patients with moderate HA and mild HA. Inv1 was absent in all patients. F8 variants were also found in 119 female carriers (FCs) (78.3%) from families related to patients with HA. There were 56 mothers (93.3%) carrying F8 variants and passing the same variants to their sons.

Conclusions These findings were the first to provide important information about the presence of Inv22 and point mutation in Vietnamese patients with HA, the mothers and their female family members. It demonstrated that genetic diagnosis and counselling for HA carriers were essential factors for future improvements in comprehensive and equitable healthcare polices for patients with HA and FCs in Vietnam.

INTRODUCTION

Haemophilia A (HA) is known as an X-linked recessive bleeding disorder caused by inherited or spontaneous variants in the F8 gene.1 Severe HA (concentration of FVIII <0.01 IU/mL)2 was characterised by frequent spontaneous haemorrhage or abnormal bleeding after an injury or surgical intervention, and it was possibly life-threatening without timely diagnosis. Typically, this disease, identified by coagulation factor assay and clinical evaluations, causes heavy and prolonged bleeding symptoms for men. In female carriers (FCs), bleeding symptoms can manifest unclearly and occur in cases such as operations, tooth extractions, tonsillectomy and primary postpartum haemorrhage.3–5 It is necessary to assess bleeding risk for HA carriers to give early diagnosis and support medical care. However, measurement of coagulation factor activity levels in patients with mild HA and FC are not simple. Mild HA cases have FVIII activity levels between 0.5 and 0.40 IU/mL, and others have nearly normal levels (over 0.40 IU/mL).6 In women, concentration of FVIII is changed by factors including age, ABO blood type, menstrual cycle, pregnancy and physiological condition.4 5 FCs may be asymptomatic but are at risk of transferring the haemophilia mutant gene to their sons. Thus, some studies recommended that genetic analysis should be performed as soon as possible to determine accurate variants in F8 gene for women in haemophilia family and prevent serious complications for patients with HA.3 5 6

In Vietnam, data from a report of National Survey of Haemophilia in 2019 showed that there were over 6000 Vietnamese patients with HA and the morbidity rate has been increasing. At present, bleeding treatment for patients with HA is improved better; however, healthcare services for them and their family members are still limited. This limitation is due to the fact that only male patients are more attentive to be given treatment than female patients. Furthermore, HA diagnosis needs an effective tool for HA carrier screening and diagnosis. In addition, coagulation factor tests are traditionally performed in Vietnam but detect only severe HA cases. The information about FC is a new concept in Vietnam. There have not been yet any study about genetic diagnostics or genetic counselling to examine the carrier status for Vietnamese patients with HA as well as FC. In high-income countries, quality medical care and treatment policies for patients with HA give advances for increasing life expectancy and reducing mortality rate.7 The application of appropriate molecular analysis methods will bring many benefits about healthcare, treatment and developing preventive health programmes to decrease the morbidity and mortality rate of haemophilia.8 9

For instance, the report of Luu et al showed that intron 22 inversion (Inv22) was found in 34% of patients with severe HA at North Vietnam but lacks data from other areas of the country.10 Therefore, this study was conducted in South Vietnam in order to (1) determine genetic variants in Vietnamese patients with HA from genetic information in the article of Luu et al; (2) choose efficiency molecular techniques for HA diagnosis in Vietnam by the combination of inversion PCR (I-PCR), multiplex PCR (M-PCR) and direct sequencing; and (3) provide a useful reference
database of the carrier status to improve genetic counselling and prenatal diagnosis programme for haemophilia FC.

MATERIALS AND METHODS
Sample collection
Procedure of sample collection and genetic analysis were shown in figure 1. From historical patient records of hospitals and medical centres at South of Vietnam, male patients that clinically diagnosed with HA were recruited to the study and divided into severe HA group or moderate and mild group. Genetic analysis was performed in both groups of patients and female members of their families such as mother, aunt, sister, and grandmother if their results were the presence of variants in \( F_8 \). After informed consent, 2 mL peripheral blood of every participant was collected separately in EDTA (1.5 mg/mL) anticoagulant tube for genetic analysis.

Procedure of identifying variants in \( F_8 \)
From peripheral blood, DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen). The concentration and purity of extracted DNA were determined by using the photometric method on the NanoDrop 2000 machine with the following parameters: DNA concentration of 300–380 ng/mL; Evaluate the purity by the rate of A260/280 nm = 1.8–2.0.

We used the I-PCR kit (Promega Wizard Genomic DNA Purification Kits, USA) to detect Inv22 as protocol described by Rossetti et al. If the sample was negative for Inv22, M-PCR would be the next method to evaluate intron 1 inversion (Inv1). We designed the primer pairs of sequence and location as the study of Bagnall et al. Primers were checked via SNPCheck3 software to recognise the presence of SNP on primers and run OligoAnalyzer V.3.1 of IDT in order to measure the ΔG value of the secondary structure. All values of length, % Guanine-Cytosine (GC), Melting Temperature (Tm), and specificity of primers are calculated by the Primer-BLAST tool on National Center for Biotechnology Information (NCBI).

Negative samples for Inv22 and Inv1 were subjected to sequencing all exon and exon-intron boundaries of \( F_8 \) to screen point mutations by M-PCR. PCR was performed on the DNA samples of the patients by using primer pairs of 23 fragments of \( F_8 \). Amplified fragments were subjected to direct sequencing in two directions by Big Dye Terminator V.3.1 kit of Applied Biosystems and read DNA sequences by ABI 3500 Genetic Analyzer. The sequencing results were analysed by CLC Main Workbench V.5.

RESULTS
Identification of variants in groups of patients with HA
A total of 71 patients who were diagnosed with HA (50 severe, 15 moderate and 6 mild) and 152 female members (from HA families) participated in this study. As described in figure 2, based on molecular techniques, the study found
60/71 patients with genetic variant F8, accounting for 84.5%. Eleven patients (15.5%) had no variants. In the group with 50 patients with severe HA, most variants in F8 were Inv22 (44%). The point mutation had 22 identified cases (11 frameshifts, 7 missense, 3 nonsense and 1 splice site) and was found in exon 14 higher than other exons. Otherwise, in the groups of 16 patients with moderate and mild HA, missense mutation was a major cause of almost moderate (8/12) or mild (3/4) cases. Details of the summary of point mutations for each group are shown in tables 1 and 2. None of the patients with HA had Inv1.

With regard to point mutation particularly, the study was the first to record two new variants (as represented in tables 1 and 2), including a nonsense variant in exon 13 (c.2025T>A) and a false mutation p.Ser1484Gly at exon 14 that have not been published in variant databases.

**Assessment of variants in FC**

From the results of genetic analysis in patients with HA, this study also determined the carrier status of 152 female members and relevant variants in the HA family. The proportion of those that had the heterozygous genotype in F8 variants was 119/152 (78.3%). Remarkably, in mutated patients, 93.3% of the mothers were obligate carriers with the same mutation of their sons. On the other hand, in the group of patients with severe HA, Inv22 not only occurred in patients and their mothers but also in female members (shown in figure 2).

**DISCUSSION**

Among low-health resource countries such as Vietnam, early diagnosis of the variants in F8 (including Inv22) was the necessary solution to have appropriate prophylaxis treatment and to improve the quality of life for patients with HA. The present study was successful in both identifying popular variants in the F8 gene that caused disease in patients with HA and analysing genetic information for FC in HA families in Vietnam.

First, similar to the report of Luu et al., the results of our study demonstrated that Inv22 was the main variant of Vietnamese patients with severe HA (44%). Besides, effective combination of molecular techniques indicated that I-PCR was the simple and convenient method, which should be considered as a priority choice over other methods.

**Table 1** Type and nucleotide of variants on F8 in the group of patients with severe haemophilia A that was detected by sequencing method (n=22)

| ID  | Variant type | Variant classification | Exon, domain |
|-----|--------------|------------------------|--------------|
| Hem01 | Deletion    | Ex14: c.4121_4124delTAGA/p.Ile1374thrfs*49 | 14, B |
| Hem03 | Insertion    | Ex14: c.2777_2778 insC/p.Ser927lysfs*7 | 14, B |
| Hem04 | Splice site  | IVSS: c.670+1G>T Intron 5 |            |
| Hem10 | Deletion    | Ex14: c.3965delA/p.Gln1322Argfs*13 | 14, B |
| Hem15 | Missense    | Ex23: c.6545G>A p.Arg2182His | 23, C1 |
| Hem16 | Duplication | Ex14: c.4825dupA/p.Lyr1609Argfs*29 | 14, B |
| Hem21 | Duplication | Ex14: c.4379dupA/p.Asn1460lysfs*2 | 14, B |
| Hem23 | Nonsense    | Ex13: c.2025T>A/p.Asp675stop | 13, A2 |
| Hem25 | Duplication | Ex14: c.3870dupA/p.Gly1291Argfs*29 | 14, B |
| Hem27 | Deletion    | Ex8: c.1141delGp, Asp381Metfs*5 | 8, a1 |
| Hem30 | Insertion    | Ex8: c.1096_1097insGp Asp366Gly*fr | 8, a1 |
| Hem34 | Deletion    | Ex14: c.4512delGp, Leu1504Phefs*63 | 14, B |
| Hem35 | Missense    | Ex8: c.2666C>Ap, Gly89Asp | 3, A1 |
| Hem39 | Nonsense    | Ex7: c.812C>A/p. Ser271Stop | 7, A1 |
| Hem40 | Duplication | Ex14: c.3637dupA/p.Ile1213Asrsfs*28 | 14, B |
| Hem46 | Missense    | Ex12: c.11891A>G/p.Asn3631Asp | 12, A2 |
| Hem50 | Nonsense    | Ex14: c.4027G>T/p.Glu1343Stop | 14, B |
| Hem52 | Deletion    | Ex14: c.3637delA/p.Ile1213Phefs*5 | 14, B |
| Hem53 | Missense    | Ex8: c.1778T>A/p.Ile593Asn | 8, A2 |
| Hem56 | Missense    | Ex1: c.1436G>A/p.Arg48lys | 1, A1 |
| Hem60 | Missense    | Ex14: c.4156C>T/p.Gln1386Stop | 14, B |
| Hem64 | Missense    | Ex8: c.446C>T/p.Pro149Leu | 4, A1 |
in testing Inv22 on these patients and consisted of recommendations from the study of Abdulqader et al.14 However, Inv22 occurred in different proportions of every population, depending on detection technique. For example, the frequency of Inv22 among studied patients was consistent with some other reports from China (44.7% by long-distance PCR (LD-PCR)),15 Mexico (45% by LD-PCR),16 Iraq (46.7% by inverse shifting PCR (IS-PCR))14 and Egypt (42.8% by IS-PCR),17 but was lower than that from Arab (55% by M-PCR)18 and higher than that from UK (38% by PCR + Real-Time PCR (RT-PCR)),19 Palestine (36.6%) by S-PCR)13 and Egypt (33% by LD-PCR).20 In Inv22-negative cases, Multiplex PCR (M-PCR) was the next test to analyse Inv1, but this variant was not to be found in our current study. As mentioned previously, the prevalence rate of Inv1 in severe HA cases was below 5%,13 18 19 which consisted of the absence as described in the present study and other populations.17 21 Surprisingly, our study did not identify any variant in the F8 gene of 11 patients (6 severe, 3 moderate and 2 mild) accounting for 15.5%. This rate was higher than the report from Germany (2%).22 This was likely due to the pathogenic variant located deep inside the introns, while the extracted and amplified sequence in this study was DNA.

In order to determine these variants, analysis of the patient’s mRNA was necessary. In addition, the undetectable variants could be other proteins involved in folding, transporting, secreting and weakening F8 such as thrombin and von Willebrand factor (vWF).23 24 These were a promising research direction for us in the future by coordinating many other methods to determine mutant locations in the intron region. In 60 male patients with haemophilia having the F8 variant, we identified two novel mutations, including c.2025T>A (p.Tyr675Stop) and c.4450A>G (p.Ser1484Gly), which have not been published on any database of genetic mutation F8.

Table 2 Type and nucleotide of variants on F8 causing moderate (n=12) and mild (n=4) haemophilia A

| ID   | Severity level | Variant type | Variant classification | Exon, domain |
|------|----------------|--------------|------------------------|--------------|
| Hem12| Moderate       | Missense     | 3′-UTR exon 26: c.8899G>A | 3′-UTR exon 26 |
| Hem14| Moderate       | Deletion     | Ex13: c.2009_2011delTCT/p.Val670del | 13, A2  |
| Hem42| Moderate       | Missense     | Ex8: c.1117G>A/p.Arg391His | 8, A1 |
| Hem43| Moderate       | Missense     | Ex14: c.4450A>G/p.Ser1484Gly | 14, B |
| Hem48| Moderate       | Missense     | Ex2: c.2236G>T/p.Arg749Glu | 2, A1 |
| Hem54| Moderate       | Missense     | Ex8: c.1063G>A/p.Arg336Cys | 8, A1 |
| Hem59| Moderate       | Missense     | Ex13: c.1963G>T/p.Tyr655His | 13, A2 |
| Hem61| Moderate       | Missense     | Ex12: c.1801A>G/p.Asn601His | 12, A2 |
| Hem63| Moderate       | Splice site  | IVS14: c.5220–1G>C    | Intron 14  |
| Hem67| Moderate       | Missense     | Ex24: c.6694C>T/p.Glu2232Stop | 24, C2 |
| Hem68| Moderate       | Missense     | Ex24: c.6682C>T/p.Glu2228Stop | 24, C2 |
| Hem70| Moderate       | Missense     | Ex25: c.6870G>T/p.Trp2290Cys | 25, C2 |
| Hem24| Mild           | Missense     | Ex2: c.386A>T/p.Asp75Tyr | 3 |
| Hem37| Mild           | Missense     | Ex14: c.5093T>C/p.Ile1698Thr | 14, B |
| Hem49| Mild           | Missense     | Ex14: c.5093T>C/p.Ile1698Thr | 14, B |
| Hem65| Mild           | Deletion     | Ex14: c.4976delC/p.Pro1659Hisfs*4 | 14 |

Figure 3 Sequencing results of new variants in F8. (A) Hem23 patient carried a novel variant that a single-nucleotide substitution from T to A at position c.2025 changes TAT trio encode tyrosine to TAA. It was caused by stopping transcript at exon 13 encode of A2 region. (B) Hem43 patient carried a new point mutation at exon 14 (c.4450A>G) that codon AGT changed to GGT, expression p.Ser1484Gly. (C) A frameshift variant in Hem65, c.4976delC on exon 14 of F8 gene. (D) Variant in Hem65’s mother.
with HA that were autologous mutant. For instance, the mother of the patient with Hem01 was a benign person that carried the heterogeneous genotype of variant c.4121_4124delTAGA on exon 14, which deflected the translation frame and completely changed the amino acid sequence from region B onwards. This mutated gene was transmitted from the mother to the patient with Hem01. However, his sister had a completely normal genotype. Specially, the patient with Hem65 carried a variant at position c.4976 delC on exon 14 (deviation from codon 1659) of the F8 gene, but his mother had no mutation at this position (figure 3C,D). It was due to the fact that a de novo mutation occurred during gametogenesis of the patient’s mother. De novo mutations account for about one-third of the cases with point mutations and small segment insertion/deletion mutations in severe, moderate and mild HA cases.25 Accordingly, it was seriously various because of carriers as the first generation that continued to inherit this mutation for the following generations. Finally, regarding these findings, molecular genetic diagnosis for patients with severe HA showed that Inv22 was a damage variant that not only occurred on patients but also on female members such as mothers, aunts and aunts’ daughters (as presented in figure 2 and figure 4). In case of all carriers included in this study, when they married or got pregnant, they should discuss with the consulting doctor about prenatal diagnosis methods to detect the abnormal fetus and to be supported with treatment during pregnancy in order to improve the quality of life of the baby in the future. In accordance with previous findings, accurate genetic carrier diagnosis was the helpful test to ensure the need for adopting early and was a screening strategy for newborn infants of families at risk in low-income countries.13 18 In brief, the current study was the first to demonstrate transmission of the Inv22 variant in the pedigree of Vietnamese haemophilic families. At present, from the findings of this study and those of Luu et al, some antenatal counselling and screening strategies for HA are conducted by our colleagues in Vietnam.

CONCLUSIONS

Our study found that Inv22 was the major genetic variant of patients with severe HA in South Vietnam, which was consistent with a previous report in North Vietnam and other populations in the world. Besides, our findings were the first to successfully apply technical procedures to identify Vietnamese HA FCs, transmission of Inv22 and point mutation that occurred in both patients with severe HA and their family members. Furthermore, the study’s results provided the necessary databases to establish a screening programme or genetic counselling programme for these carriers.

Take home messages

⇒ Genetic characteristics in female Vietnamese haemophilia carriers have not been analysed yet.
⇒ Intron 22 inversion (Inv22) is the major genetic variant of patients with severe haemophilia A (HA) in South Vietnam.
⇒ Transmission of Inv22 and point mutation occurred in both patients with severe HA and their family members.
⇒ It is necessary to establish a screening programme or a genetic counselling programme for female carriers.

Handling editor Mary Frances McMullin.

Acknowledgements The authors acknowledge the University Medical Centre, Ho Chi Minh City University of Medicine and Pharmacy, Ho Chi Minh City Department of Science and Technology and Ho Chi Minh City Hospital of Haematology and Blood Transfusion in Vietnam for supporting data collection and cost of genetic analysis for the participants.

Contributors BHN, BSTN contributed to planning, conduct and writing of the manuscript; NH, XTL, HHN contributed to the design and to the analysis of the results; C-MTN contributed to edit language of the manuscript. BSTN is responsible for the overall content as the guarantor.

Funding This research is funded by the cost of genetic analysis for the participants by the Ho Chi Minh City Department of Science and Technology, Vietnam.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Our study was approved by the University of Medicine and Pharmacy HCM City Ethics Review Committee (approval number #2014–61).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. All data relevant to the study are included in the article. Data obtained from our work in clinical laboratory department at University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Bac Hoang Nguyen http://orcid.org/0000-0003-2802-9510

REFERENCES

1 McVey JM, Raillapalli PM, Kembell-Cook G, et al. The European association for haemophilia and allied disorders (EAHAD) coagulation factor variant databases: important resources for haemostasis clinicians and researchers. Haemophilia 2020;26:306–13.
2 Galen KPM, d’Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH. J Thromb Haemost 2021;19:1883–7.
3 Renault NK, Dyack S, Dobson MJ, et al. Heritable skewed X-chromosome inactivation leads to haemophilia A expression in heterozygous females. Eur J Hum Genet 2007;15:628–37.
4 Plug I, Mauser-Bunschoten EP, Bröcker-Links, AHJT, et al. Bleeding in carriers of hemophilia. Blood 2006;108:52–6.
5 Ostasik KH, Schiebel E, Ingerslev J, et al. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B. Thromb Haemost 2000;83:433–7.
6 Benson G, Auerwald G, Dolan G, Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus 2018;16:535–44.
7 Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010;16:437–46.
8 Shaj RJ, Jayandharan G, George B. Informativeness of linkage analysis for genetic diagnosis of haemophilia A in India. Haemophilia 2004;10:553–9.
9 Husain N. Carrier analysis for hemophilia A: ideal versus acceptable. Expert Rev Mol Diagn 2009;9:203–7.
10 Luu DV, Tran TH, Nguyen DH, et al. Mutation characteristic of 103 haemophilia a patients in Vietnam: identification of novel mutations. *Haemophilia* 2019;5:e274–7.

11 Rossetti LC, Raddi CP, Lamipa IB, et al. Genotyping the hemophilia inversion hotspot by use of inverse PCR. *Clin Chem* 2005;51:1154–8.

12 Bagnall RD, Waseem N, Green PM, et al. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia a. *Blood* 2002;99:168–74.

13 Mahmoud Abu Arar C, Samarah F, Sudqi Abu Hasan N. Factor VIII intron 22 inversion in severe hemophilia A patients in Palestine. *Scientifica* 2020;2020:3428648.

14 Abdulqader AMR, Mohammed AI, Rachid S, et al. Identification of the intron 22 and intron 1 inversions of the factor VIII gene in Iraqi Kurdish patients with hemophilia a. *Clin Appl Thromb Hemost* 2020;26:e107602961988829.

15 Feng Y, Li Q, Shi P, et al. Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China. *Haemophilia* 2021;27:e88–92.

16 Mantilla-Capacho JM, Beltrán-Miranda CP, Luna-Záizar H, et al. Frequency of intron 1 and 22 inversions of factor VIII gene in Mexican patients with severe hemophilia a. *Am J Hematol* 2007;82:283–7.

17 Mosaad RM, Amr KS, Rabie EA, et al. Genomic alterations in the F8 gene correlating with severe hemophilia A in Egyptian patients. *Mol Genet Genomic Med* 2021;9:e1575.

18 Abu-amero KK, Hellani A, Al-Mahed M, et al. Spectrum of factor VIII mutations in Arab patients with severe haemophilia a. *Haemophilia* 2008;14:484–8.

19 Green PM, Bagnall RD, Waseem NH, et al. Haemophilia a mutations in the UK: results of screening one-third of the population. *Br J Haematol* 2008;143:115–28.

20 Sherief LM, Gaber OA, Youssef HM, et al. Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role? *Ital J Pediatr* 2020;46:129.

21 Qadir OH, Agi E, Bolhassani A. Genotyping of intron 1 and 22 inversion of factor VIII gene using IS-PCR in Kurdish patients of Iraq. *EurAsian J Biosci* 2020;14:1181–5.

22 Uen C, Oldenburg J, Schröder J, et al. [2% Haemophilia A patients without mutation in the FVIII gene]. *Hamostaseologie* 2003;23:1–5.

23 Margaglione M, Castaman G, Morfini M, et al. The Italian AICE-Genetics hemophilia a database: results and correlation with clinical phenotype. *Haematologica* 2008;93:p722–8.

24 Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. *J Intern Med* 2005;257:209–23.

25 Castaldo G, D’Argenio V, Nardiello P, et al. Haemophilia A: molecular insights. *Clinical Chemical Laboratory Medicine* 2007;45:450–61.